Viatris (VTRS) Intangibles (2019 - 2026)
Viatris' (VTRS) quarterly Intangibles came in at $14.5 billion in Q1 2026, down 13.08% year-on-year from $16.7 billion in Q1 2025, and down 4.1% quarter-over-quarter from $15.1 billion in Q4 2025.
Viatris (VTRS) Intangibles (2019 - 2026) Analysis & Trends
Viatris' Intangibles history runs 8 years deep, the most recent figure standing at $14.5 billion for Q1 2026.
- On a quarterly basis, Intangibles fell 13.08% year-over-year to $14.5 billion in Q1 2026; TTM through Mar 2026 was $14.5 billion, a 13.08% decrease from a year earlier, with the FY2025 full-year figure at $15.1 billion, down 11.53% from the prior year.
- Intangibles declined to $14.5 billion in Q1 2026 per VTRS's latest filing, from $15.1 billion in the prior quarter.
- Across five years, Intangibles topped out at $25.3 billion in Q1 2022 and bottomed at $14.5 billion in Q1 2026.
- The 5-year median for Intangibles is $19.1 billion (2024), against an average of $19.5 billion.
- Across the five-year window, Intangibles retreated 7.53% in 2023 and fell 16.6% in 2024, its largest moves.
- Year by year, Intangibles stood at $22.6 billion in 2022, then slipped by 15.15% to $19.2 billion in 2023, then decreased by 11.0% to $17.1 billion in 2024, then fell by 11.53% to $15.1 billion in 2025, then decreased by 4.1% to $14.5 billion in 2026.
- Per Business Quant, the three latest VTRS Intangibles figures stand at $14.5 billion (Q1 2026), $15.1 billion (Q4 2025), and $15.7 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 34.07 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.61 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 959.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 21.80 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 473.93 Mn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 14.48 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.23 Bn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 78.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.48 Bn |
| Dec 31, 2025 | 15.10 Bn |
| Sep 30, 2025 | 15.72 Bn |
| Jun 30, 2025 | 16.32 Bn |
| Mar 31, 2025 | 16.66 Bn |
| Dec 31, 2024 | 17.07 Bn |
| Sep 30, 2024 | 17.98 Bn |
| Jun 30, 2024 | 18.42 Bn |
| Mar 31, 2024 | 19.13 Bn |
| Dec 31, 2023 | 19.18 Bn |
| Sep 30, 2023 | 21.28 Bn |
| Jun 30, 2023 | 22.08 Bn |
| Mar 31, 2023 | 22.70 Bn |
| Dec 31, 2022 | 22.61 Bn |
| Sep 30, 2022 | 23.01 Bn |
| Jun 30, 2022 | 24.10 Bn |
| Mar 31, 2022 | 25.25 Bn |
| Dec 31, 2021 | 26.13 Bn |
| Sep 30, 2021 | 26.99 Bn |
| Jun 30, 2021 | 27.86 Bn |